Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vacc

https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1 

Thsi article is a preprint and has not been peer-reviewed

Key take aways:

1. Study endpoints reported here are vaccine efficacy (VE) against laboratory-confirmed COVID-19
2. No report on how this vaccine can reduce severe COVID: patient hospitalization, ICU admission, and death
3. Decreased appetite, lethargy, asthenia, malaise, night sweats, and hyperhidrosis wre new adverse events not previously identified in earlier reports
4. During the blinded, controlled period, 15 BNT162b2 and 14 placebo recipients died; during the open-label period, 3 BNT162b2 and 2 original placebo recipients who received BNT162b2 after unblinding died - this means no impact on COVID related death between vaccined and unvaccined control group - probably data size is too small
5. Some of the test group already had previousl COVID infection (3% of the tested people), among them, 19 had COVID infection again during the testing period: 2 cases in vaccine and 7 in placebo recipients - this is really small data size but was used to spport the current practice of immunizing without screening for evidence of prior infection 

所有跟帖： 

• 你引用的文章，我截屏，劃重點。 -TBz- ♂ (108 bytes) () 08/02/2021 postreply 15:41:41

• 同意 有很多重點可以劃 角度不同 -BiologistMom- ♂ (0 bytes) () 08/02/2021 postreply 17:13:28